This platform has two clean rooms dedicated to the production of Advanced Therapy Medicinal Products (ATMPs). It supports the manufacturing of new biological drugs developed by the RIGHT unit. It operates downstream of the EFS Biotherapy Innovation Platform, which enables the transition from “research-grade” to “clinical-grade” medicinal products.
Two clinical studies using biological drugs have previously been conducted thanks to the partnership between the research unit and the production platform. These include the TKO study (suicide gene to prevent graft-versus-host disease) and the NK-EGFR01 study (ClinicalTrials.gov Identifier: NCT02845999, portal injection of allogeneic NK cells and cetuximab antibody in gastrointestinal cancers with liver metastases).

